RheumNow Day 3 Recap ACR Convergence 2024 Highlights
Nov 19, 2024
auto_awesome
Joining the discussion are Bella Mehta, a New York rheumatologist specializing in autoimmune diseases, Brian Jaros from Chicago, an expert in giant cell arteritis, and Quilin Conley from Galway, focusing on anti-obesity medications. They delve into new lupus nephritis recommendations and explore the interplay between psoriatic arthritis and immunotherapy mortality risks. Additionally, advancements in predicting vision loss in giant cell arteritis are discussed, alongside the potential of GLP-1 medications to benefit rheumatoid arthritis patients, despite challenges like side effects.
Recent guidelines on lupus nephritis stress the importance of understanding disease classes 3, 4, and 5 for effective patient management.
A significant study indicates safe use of immune checkpoint inhibitors in autoimmune patients, despite a noted increase in mortality risks initially.
Deep dives
New Recommendations for Lupus Nephritis
Recent guidelines on the diagnosis and treatment of lupus nephritis were highlighted as a significant development during the conference. This session focused on the nuances of managing classes 3, 4, and 5 of the disease, which are critical for patient care. The expert faculty emphasized that further resources on this topic are available for those interested in deepening their understanding. Given the complexity and importance of effective management strategies for lupus nephritis, these recommendations are essential for rheumatology practitioners.
Impact of Immune Checkpoint Inhibitors on Autoimmune Diseases
A major study assessed the mortality risks associated with administering immune checkpoint inhibitors to patients with pre-existing autoimmune diseases. Data from over 25,000 patients indicated a slight increase in mortality among those with autoimmune conditions; however, this difference diminished after adjusting for various risk factors such as diabetes and cardiovascular issues. This finding supports the notion that checkpoint inhibitors can be safely administered to this patient population, alleviating concerns over mortality. Nevertheless, the need for careful management of potential inflammatory reactions in these patients remains a priority.
Weight Management in Rheumatoid Arthritis Patients Using GLP-1 Medications
A retrospective study explored the effects of anti-obesity medications, specifically semaglutide and terzepatide, on rheumatoid arthritis patients, revealing promising results in weight reduction and overall inflammatory markers. Although around 25% of participants discontinued their therapy mainly due to gastrointestinal side effects and access issues, the study indicates a growing interest in the intersection between weight management and rheumatologic care. The potential anti-inflammatory benefits associated with these medications prompt considerations for their integration into treatment regimens. As this area of research expands, it may significantly influence how clinicians manage patients with inflammatory diseases.
Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.
Join us live and stay at the forefront of rheumatology!
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode